![Guilherme Nader Marta: Our Review On the PI3K/Akt-targeted Agents](https://oncodaily.com/pub/uploads/2024/06/Nader-Marta-e1718349870167.png)
Photo taken from Photo from Guilherme Nader Marta/X
Jun 14, 2024, 03:24
Guilherme Nader Marta: Our Review On the PI3K/Akt-targeted Agents
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X:
“PI3K/Akt-targeted agents entered clinical practice & may soon bring precision oncology to 1st line of Tx for ER+ breast cancer
Out in Critical Reviews in Oncology Hematology (CROH) our review on the activity, biomarkers & toxicities w/ these agents & next steps in the field”
Read further.
Source: Guilherme Nader Marta/X
Jul 4, 2024, 00:09